前列地尔对慢性肺源性心脏病肺动脉高压疗效的临床研究  

Clinical study of effect of alprostadil on pulmonary hypertension of chronic pulmonary heart disease

作　　者：章敬玉[1] 罗勇[1] 

机构地区：[1]上海交通大学附属新华医院崇明分院呼吸科,上海202150

出　　处：《临床肺科杂志》2014年第8期1383-1385,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨前列地尔对慢性肺源性心脏病肺动脉高压的治疗效果,为临床提供参考。方法选择慢性肺源性心脏病伴肺动脉高压患者130例,随机分为两组,每组65例,对照组进行常规治疗,治疗组在对照组治疗基础上给予前列地尔治疗,比较两组疗效。结果治疗组患者治疗后,其DPAP、SPAP和MPAP的值分别为(11.9±2.5)mmHg、(28.6±3.8)mmHg、(16.3±2.5)mmHg,均较治疗前显著降低;对照组患者治疗后,其DPAP、SPAP和MPAP的值分别为(17.2±3.1)mmHg、(35.9±7.2)mmHg、(31.9±6.1)mmHg,均较治疗前显著降低;治疗组治疗后,DPAP与SPAP显著低于对照组;治疗组治疗后,PaO2、FEV1、FEV1/FVC的值分别为(66.84±8.03)mmHg、(81.41±11.13)%、(90.52±13.51)%,较治疗前显著升高,PaCO2值为(52.50±7.11)mmHg,较治疗前显著降低;对照组治疗后,PaO2、FEV1、FEV1/FVC的值分别为(55.88±7.72)mmHg、(77.39±12.11)%、(79.25±11.01)%,较治疗前显著升高,PaCO2值为(56.6±0.42)mmHg,较治疗前显著降低;治疗组患者治疗后的PaO2值显著高于对照组,差异均有统计学意义(P<0.05)。结论前列地尔治疗慢性肺源性心脏病肺动脉高压疗效显著,患者不良反应少,其临床效果优于常规治疗,用药后患者肺动脉压明显降低,症状得到明显缓解,说明前列地尔注射液在治疗慢性肺源性心脏病肺动脉高压方面具有较高的临床应用价值。Objective To investigate the therapeutic effect of alprostadil on pulmonary hypertension of chronic pulmonary heart disease. Methods 130 patients with pulmonary hypertension of chronic pulmonary heart disease were randomly divided into two groups,65 cases in each group. The control group was given conventional treatment,while the treatment group was additionally treated with alprostadil. The efficacy of the two groups was compared. Results After the treatment,the values of DPAP,SPAP and MPAP of the treatment group were（ 11. 9 ±2. 5） mmHg,（ 28. 6 ± 3. 8） mmHg,and（ 16. 3 ± 2. 5） mmHg,which were significantly lower than those before treatment. The values of DPAP,SPAP and MPAP of the control group were（ 17. 2 ± 3. 1） mmHg,（ 35. 9 ± 7. 2）mmHg and（ 31. 9 ± 6. 1） mmHg,significantly lower than those before the treatment as well. The values of DPAP and SPAP were significantly lower in the treatment group than in the control group. The values of PaO2,FEV1and FEV1/FVC in the treatment group increased to 66. 84 ± 8. 03 mmHg,81. 41% ± 11. 13% and 90. 52% ± 13. 51%,and the value of PaCO2decreased to 52. 50 ± 7. 11 mmHg after the treatment. The values of PaO2,FEV1and FEV1/FVC increased to 55. 88 ± 7. 72 mmHg,77. 39 ± 12. 11% and 79. 25 ± 11. 01%,and the value of PaCO2decreased to 56. 6± 0. 42 mmHg respectively in the control group. The value of PaO2was significantly higher in the treatment group than in the control group（ P〈0. 05）. Conclusion Alprostadil injection shows good curative effect in the treatment of patients with pulmonary hypertension of chronic pulmonary heart disease,with less adverse reactions.

关 键 词：慢性肺源性心脏病 肺动脉高压 前列地尔 疗效 

分 类 号：R541.5[医药卫生—心血管疾病] R544.1[医药卫生—内科学]